GlaxoSmithKline Breaks Out of Its Small-Molecule Mind-Set

Following similar moves by many of its Big Pharma peers, GSK is buying into large molecules, big time. In December 2006, it paid $454 million in cash for next-generation antibody specialist Domantis. Later that month, the pharmaceutical firm committed over $2 billion in up-fronts, milestones, and equity for an antibody program from Genmab AS. For investors in privately held Domantis, whose most advanced drug candidate is preclinical, the acquisition was a much earlier than-anticipated exit.

Following similar moves by many of its Big Pharma peers, GlaxoSmithKline PLC is buying into large molecules, big time. In December 2006, it paid £230mm ($454 million) in cash for next-generation antibody specialist Domantis Ltd.[See Deal] Later that month, the pharmaceutical firm committed over $2 billion in up-fronts, milestones, and equity for Genmab AS ' HuMax-CD20 (ofatumumab) fully human monoclonal antibody, plus other anti-CD20 antibodies that GenMab may develop. [See Deal](See "Genmab/GSK: An Impressive Display of Biotech’s Increased Leverage," IN VIVO, January 2007 Also see "Genmab/GSK: An Impressive Display of Biotech's Increased Leverage" - In Vivo, 1 January, 2007..)

The Domantis acquisition was GSK’s first external transaction in the area and a direct consequence of an internal review by...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.